In the Pipeline
In the Pipeline
The following drugs are still in clinical trials:
New indication for chemotherapy agent Xeloda (capecitabine) by Hoffman-La Roche. Supple men tal New Drug Application seeks approval as a twice-daily oral treatment for first-line metastatic colorectal cancer. In one Phase III trial group, drug led to 50% tumor reduction in 21% of patients vs. 11% receiving 5-FU Leucovorin. Cautions include use in pregnant patients or patients taking warfarin. Side effects included hand-foot syndrome, diarrhea, stomatitis, and bone marrow suppression. Increases in bilirubin and decreases in red and white blood cells commonly reported. Xeloda is approved for metastatic breast cancer treatment in patients unresponsive to paclitaxel and doxorubicin.
Macular degeneration treatment Visudyne (verteporfin) by CIBA Vision. FDA has assigned priority review status to the company’s New Drug Application for the indication of wet age-related macular degeneration by subfoveal choroidal neovascularization. The treatment regimen includes IV injection followed by activation by laser light.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.